The stock of Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) hit a new 52-week low and has $2.60 target or 14.00% below today’s $3.02 share price. The 9 months bearish chart indicates high risk for the $37.74 million company. The 1-year low was reported on Oct, 19 by Barchart.com. If the $2.60 price target is reached, the company will be worth $5.28M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 18,464 shares traded hands. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) has declined 23.95% since March 16, 2016 and is downtrending. It has underperformed by 29.49% the S&P500.
Analysts await Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) to report earnings on November, 10.
According to Zacks Investment Research, “Imprimis Pharmaceuticals, Inc. is a pharmaceutical company focused on its proprietary ophthalmology and urology drug formulations. Imprimis recently launched its urology business, which includes a patented formulation to address patients suffering from interstitial cystitis.”
Insitutional Activity: The institutional sentiment increased to 1.2 in 2016 Q2. Its up 0.06, from 1.14 in 2016Q1. The ratio increased, as 3 funds sold all Imprimis Pharmaceuticals Inc shares owned while 2 reduced positions. 1 funds bought stakes while 5 increased positions. They now own 1.66 million shares or 37.14% less from 2.64 million shares in 2016Q1.
Pnc Fincl Svcs Gp has 0% invested in the company for 2,000 shares. Marathon Mgmt owns 25,000 shares or 0.05% of their US portfolio. The California-based Granite Prns Lc has invested 0.05% in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY). Manufacturers Life The has 0% invested in the company for 169 shares. Geode Mgmt Lc has 0% invested in the company for 17,570 shares. Marathon Asset Mgmt Limited Partnership accumulated 833,333 shares or 0.17% of the stock. Northern Trust has invested 0% of its portfolio in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY). Berson And Corrado Investment Advsr Ltd Liability Corp accumulated 31,107 shares or 0.08% of the stock. Opaleye Mngmt holds 265,000 shares or 0.98% of its portfolio. Creative Planning accumulated 0% or 750 shares. Blackrock Fund Advisors holds 0% of its portfolio in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 32,979 shares. Financial Bank Of America De accumulated 0% or 17,797 shares. Blackrock Inv Mgmt Ltd Llc last reported 1,966 shares in the company. Tower Lc (Trc) last reported 548 shares in the company. Vanguard Group Inc has invested 0% of its portfolio in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY).
More notable recent Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) news were published by: Prnewswire.com which released: “Imprimis Pharmaceuticals Announces Availability of Lower-Cost Option for the …” on October 17, 2016, also Quotes.Wsj.com with their article: “News Imprimis Pharmaceuticals Inc.IMMY” published on February 08, 2013, Prnewswire.com published: “Imprimis Pharmaceuticals’ Formulations to be Highlighted at Upcoming Annual …” on October 13, 2016. More interesting news about Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) were released by: Prnewswire.com and their article: “Imprimis Pharmaceuticals Strengthens Senior Leadership Team with Key Hires in …” published on August 15, 2016 as well as Prnewswire.com‘s news article titled: “Imprimis Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year …” with publication date: March 03, 2016.
IMMY Company Profile
Imprimis Pharmaceuticals, Inc. (Imprimis), incorporated on January 11, 2006, is engaged in the development, production and dispensing of compounded pharmaceuticals. The Firm operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Firm is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Firm also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas, including oncology, autoimmunity, chronic infectious diseases and endocrine and metabolic diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.